
    
      Identifying a role for NF-κB signaling in vitiligo may improve therapies for this disfiguring
      disorder. Current treatments vary in effectiveness and may not always be long lasting cases.
      The NF-κB pathway and IL-6 itself are the target of several FDA approved drugs, thus opening
      new therapeutic avenues.
    
  